Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cd117

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Cd117. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-022388-37 Sponsor Protocol Number: TUD-RELA02-048 Start Date*: 2011-09-23
    Sponsor Name:Technische Universität Dresden
    Full Title: Treatment of patients with MDS or AML with an impending hematological relapse with Azacitidin (Vidaza)
    Medical condition: Patients with AML or MDS >= 18 years of age after conventional chemotherapy or stem cell transplantation with significant residual disease or an increase of MRD (e.g. t(6,9), NPM1 or CD34+ or CD117...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060557 Acute myelocytic leukemia LLT
    20.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002452-16 Sponsor Protocol Number: PTO95105013 Start Date*: 2020-02-04
    Sponsor Name:UMC Utrecht
    Full Title: Inhibition of Mast cell Activation in AtheroScleroTic lesions using an Anti-IgE antibody approach (MAST-trial)
    Medical condition: Atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002257-23 Sponsor Protocol Number: 62063 Start Date*: 2009-01-26
    Sponsor Name:European Organization for Research and Treatment of Cancer
    Full Title: A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.
    Medical condition: Metastatic gastro-intestinal stromal tumor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003883-20 Sponsor Protocol Number: CSTI571JDE74 Start Date*: 2008-09-30
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection
    Medical condition: gastrointestinal stromal tumors - adjuvant treatment after surgical tumor resection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed) SK (Completed) CZ (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-000898-39 Sponsor Protocol Number: SSGXXII Start Date*: 2014-12-19
    Sponsor Name:Scandinavian Sarcoma Group
    Full Title: Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study.
    Medical condition: gastrointestinal stromal tumor (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing) FI (Ongoing) SE (Ongoing) ES (Ongoing) DK (Ongoing) DE (Ongoing) AT (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004162-34 Sponsor Protocol Number: AB12004 Start Date*: 2015-01-02
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, double-blind, placebo-controlled, two-parallel groups, phase III clinical trial to compare the efficacy and safety of masitinib to placebo in patients with l...
    Medical condition: stromal gastrointestinal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) CZ (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002165-20 Sponsor Protocol Number: 20040110 Start Date*: 2005-02-18
    Sponsor Name:Amgen Inc
    Full Title: An open label study of AMG 706 in subjects with advanced gastrointestinal stromal tumors (GISTs) who developed progressive disease or relapsed while on Imatinib Mesylate.
    Medical condition: Gastrointestinal stromal tumour (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004073-27 Sponsor Protocol Number: 18082A0002 Start Date*: 2019-03-13
    Sponsor Name:ARCI (trade name LYON RECHERCHE CLINIQUE : LyREC)
    Full Title: Dupilumab impact on skin resident memory T cells
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001537-15 Sponsor Protocol Number: CSTI571BDE28 Start Date*: 2006-03-14
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Open-label trial of imatinib mesylate (Glivec, formerly known as STI571) in combination with vinorelbine (Navelbine) for patients with advanced breast carcinoma
    Medical condition: carcinoma breast
    Disease: Version SOC Term Classification Code Term Level
    M15 10007305 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003774-40 Sponsor Protocol Number: TheStopGISTtrial Start Date*: 2017-06-21
    Sponsor Name:Oslo University Hospital
    Full Title: Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment
    Medical condition: Gastrointestinal stromal tumour (GIST)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020305-32 Sponsor Protocol Number: CRAD001CIT27T Start Date*: 2010-08-06
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A phase II, open label study to evaluate the activity and safety of Everolimus in association to Imatinib in PDGFRA-D842V unresectable or metastatic gastrointestinal stromal tumours (GISTs)as...
    Medical condition: patients with unresectable and/or metastatic gastrointestinal stromal tumours with exon 18 PDGFRA mutation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001725-24 Sponsor Protocol Number: CTKI258AIC02 Start Date*: 2011-10-03
    Sponsor Name:Novartis Pharma Services
    Full Title: DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib
    Medical condition: Unresectable, metastatic or recurrent gastrointestinal stromal tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FI (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003006-31 Sponsor Protocol Number: ASPIRE Start Date*: 2021-02-08
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Predictive value of colonic mucosal and synovial tissues profiles for response to JAKs inhibitor in patients affected by ulcerative colitis and concomitant peripheral arthritis
    Medical condition: Ulcerative colitis and concomitant peripheral arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10045282 UC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000283-28 Sponsor Protocol Number: IB_2013–01 Start Date*: 2013-11-13
    Sponsor Name:Institut Bergonié
    Full Title: Efficacy and Safety of PD-0332991 in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 study
    Medical condition: Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002478-20 Sponsor Protocol Number: PRECISESTUDY Start Date*: 2022-03-31
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA
    Full Title: IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY.
    Medical condition: PSORIATIC ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001372-37 Sponsor Protocol Number: ET13-024 Start Date*: 2014-06-13
    Sponsor Name:CENTRE LEON BERARD
    Full Title: A randomized, multicentre, phase III trial evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tu...
    Medical condition: GastroIntestinal Stromal Tumours (GIST)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000973-40 Sponsor Protocol Number: AB04030 Start Date*: 2008-12-18
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in...
    Medical condition: gastro-intestinal stromal tumour
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Ongoing) DE (Prohibited by CA) AT (Ongoing) BE (Prematurely Ended) ES (Prematurely Ended) NL (Temporarily Halted) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001790-41 Sponsor Protocol Number: AB11002 Start Date*: 2013-04-10
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointesti...
    Medical condition: Gastrointestinal stromal tumor resistant to imatinib
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) NL (Ongoing) DE (Prohibited by CA) BE (Prematurely Ended) AT (Ongoing) GB (GB - no longer in EU/EEA) GR (Prematurely Ended) IT (Suspended by CA) CY (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003998-96 Sponsor Protocol Number: AXAGIST Start Date*: 2019-04-03
    Sponsor Name:Centrum Onkologii – Instytut im. Marii Skłodowskiej - Curie
    Full Title: A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST
    Medical condition: GIST - unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001810-16 Sponsor Protocol Number: 62024 Start Date*: 2004-11-25
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versu...
    Medical condition: Gastrointestinal stromal tumors (GIST) are mesenchymal neoplasms usually arising from the gastrointestinal wall. Pathologically,they present with spindle cells in most cases. Immunohistochemically...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:09:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA